Kelly ServickScience’s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.Three months after retracting a high-profile COVID-19 paper, editors at The Lancet hope to assure the research community that they’ve learned their lesson.
The journal yanked a study on risks of hydroxychloroquine—an antimalarial drug whose proposed use as a COVID-19 treatment has stirred scientific and political controversy—in June when its authors couldn’t prove the underlying patient data even existed.
Yesterday, it announced policies, effective immediately, that aim to keep flawed studies using “large, real-word datasets” from slipping past peer review again.